Drugs / Detomidine
Detomidine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06262607 | Jan → Nov 2024 | pruritus, hereditary localized | Clexio Biosciences Ltd. | Completed | Missed primary |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Detomidine | “CLE-400 (Detomidine topical gel)” NCT06262607 ↗ |
| Known as | CLE-400 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06262607 ↗ |
| Known as | Detomidina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2110829 ↗ |
| Known as | Detomidine hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL2110829 ↗ |
| Known as | DETOMIDINE HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2110829 ↗ |
| Known as | MPV-253 AII | ChEMBL registry synonym — accepted as the source's own label CHEMBL2110829 ↗ |
| Modality | Small molecule | — CHEMBL2110829 ↗ |
| Route | Topical | “Topical CLE400 gel 0.28% administered once daily” NCT06262607 ↗ |